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The ability to detect, characterize, and manipulate specific biomol-
ecules in complex media is critical for understanding metabolic
processes. Particularly important targets are oxygenases (cyto-
chromes P450) involved in drug metabolism and many disease
states, including liver and kidney dysfunction, neurological disor-
ders, and cancer. We have found that Ru photosensitizers linked to
P450 substrates specifically recognize submicromolar cytochrome
P450cam in the presence of other heme proteins. In the P450:Ru-
substrate conjugates, energy transfer to the heme dramatically
accelerates the Ru-luminescence decay. The crystal structure of a
P450cam:Ru-adamantyl complex reveals access to the active center
via a channel whose depth (Ru-Fe distance is 21 Å) is virtually the
same as that extracted from an analysis of the energy-transfer
kinetics. Suitably constructed libraries of sensitizer-linked sub-
strates could be employed to probe the steric and electronic
properties of buried active sites.
Developing methods for detecting mammalian P450s andcharacterizing their structures (1) would facilitate rational
drug design (2) and the engineering of catalysts (3, 4). Although
more than 100 mammalian microsomal P450 isozymes have been
identified, direct information about their structures and physi-
ological function is lacking. Crystal structures are available for
only four P450 oxygenases (5), all of which are water-soluble
bacterial enzymes; the best characterized of these, cytochrome
P450cam, was targeted in our studies. Here, we report that
substrates linked to [Ru(bpy)3]21 (bpy is 2,29-bipyridine; Scheme
1; ref. 6) can selectively probe the enzyme in complex media.
The attachment of a sensitizer to substrate, nucleotide, or
flavin analogs should improve the ability of such small-molecule
probes (7–10) to resolve enzyme active centers while minimizing
the need for intensive synthesis, metabolite characterization, and
enzyme mutagenesis. Our modular, active-site-directed ap-
proach to detection is superior to enzyme- and antibody-based
assays: sensitizer-linked substrates assess ligand specificity and
enzyme structure and are amenable to combinatorial chemistry.
Furthermore, because Ru substrates interact with their targets
reversibly, they differ from current probes of heme proteins that
rely on covalent modification and chemical analysis (1, 11).
Materials and Methods
P450cam ExpressionyCrystallization Conditions. Pseudomonas putida
cytochrome P450cam (residues 1–414) containing the mutation
Cys334Ala (Quickchange mutagenesis, Stratagene) was overex-
pressed in Escherichia coli TBY cells from plasmid pUS200 (12)
and purified in the presence of camphor with slight modification
to procedures previously described (13). P450:Ru-C9-
adamantane (Ad) seed crystals of space group P212121 (cell
dimensions of 65.4 3 74.5 3 91.7 Å3; one molecule per asym-
metric unit; Matthews coefficient (VM) 5 2.4; solvent content 5
49%) nucleated overnight (4°C; vapor diffusion) from protein
separated from camphor and complexed with stoichiometric
Ru-C9-Ad. Hanging drops contained an equal volume mixture of
reservoir and 430 mM P450:Ru-C9-Ad in 20 mM Hepes, pH
7.5y100 mM KCly1 mM DTT. The reservoir (final pH ’6.0)
contained 100 mM NaOAc (pH 4.9), 200 mM NH4OAc (pH 7.0),
and 9–11% (wtyvol) polyethylene glycol (molecular weight
8,000). Diffraction quality crystals (0.15 3 0.15 3 0.5 mm3) were
grown over 24–48 h by moving seed crystals into sitting drops of
reduced polyethylene glycol concentrations (5–7%).
Structure Determination. An initial molecular replacement solu-
tion (correlation coefficient 5 0.53 and Rcryst 5 SiFobsu 2
uFcalciySuFobsu 5 43.4%, for 15.0- to 3.5-Å resolution data) was
found by AMORE (14) with a probe derived from the structure of
camphor-bound P450cam (PDB code: 2cpp; ref. 15) by using
diffraction data collected from P450:Ru-C9-Ad crystals (1.55-Å
resolution; overall Rsym 5 SSjuIj 2 ,I.uySSjIj 5 4.8%; overall
signal-to-noise ratio 5 IysI 5 37.4; redundancy 5 6.5; 99.2%
complete). Diffraction data were collected at 100 K on Beam-
line 7-1 (1.08 Å) of the Stanford Synchrotron Research Labo-
ratory and processed with DENZO (16). Substantial changes in the
regions of P450 distal to the heme were modeled to omit electron
density maps with XFIT (17). Ru-C9-Ad was positioned into the
remaining difference density. The structure was refined by
torsion-angle molecular dynamics and positional refinement
with CNS (18) amidst model rebuilding, water molecule place-
ment, and resolution extension to 1.55 Å. After an overall
anisotropic thermal factor correction, bulk-solvent correction,
and individual thermal factor refinement, grouped occupancy
refinement of Ru-C9-Ad and those residues in multiple confor-
mations produced the final model {4019 scatterers; 1 Ru-C9-Ad
as a superposition of the two (D and L) [Ru(bpy)3]21 enanti-
omers; 23 residues in multiple conformations; 427 water mole-
cules; 5 acetate molecules; Rcryst 5 21.6%; Rfree 5 22.6% for 8%
of the reflections removed at random; no s cutoff}. The
Abbreviations: bpy, 2,29-bipyridine; EB, ethylbenzene; Ad, adamantane; Im, imidazole; p,
excited state.
Data deposition: The atomic coordinates of the P450:Ru-C9-Ad structure have been depos-
ited in the Protein Data Bank, www.rcsb.org (PDB ID code 1qmq).
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Scheme 1. Sensitizer-linked substrates (EB, Ad) and ligands (Im).
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adamantyl moiety of Ru-C9-Ad is well ordered, but static andyor
dynamic disorder increases up the methylene chain toward the
sensitizer, where only one of the three bpy ligands is well
resolved. The ruthenium atom position was confirmed by the
largest peak in the initial Fobs–Fcalc electron density map (4s) and
also by a peak in the Bijvoet difference Fourier map (calculated
with coefficients uF1u 2 uF2u and phases fmodel 2 py2), which
identified all sulfur and metal atoms in the model. The final
model has excellent stereochemistry (root-mean-square devia-
tion from ideal bond lengths , 0.009 Å and ideal bond angles ,
1.3o) with 90.3% of all residues in the most favored regions of
fyw space, as defined by PROCHECK (19). No residues fall in
disallowed regions. Larger refined thermal (B) factors for Ru-
C9-Ad (,B. 5 48.2 Å2) compared with the overall model (,B.
5 28.0 Å2; ,B.mainchain 5 19.4 Å2; ,B.sidechain 5 20.4 Å2)
reflect the mobility and conformational heterogeneity of the
bound [Ru(bpy)3]21. The ribbon representation (Fig. 1) was
generated with MOLSCRIPT (20) and RASTER3D (21).
Energy-Transfer Measurements. Solution experiments were per-
formed under an argon atmosphere with P450 and Ru substrate
in 100 mM KCly20 mM potassium phosphate buffer, pH 7.4.
Single-crystal experiments were conducted aerobically. Samples
were excited with XeCl excimer-pumped dye laser pulses (25 ns;
480 nm; 1–2 mJ per pulse). The emission decay traces were fit to
the biexponential function, y 5 c0 1 c1e2(ken 1 k0)t 1 c2e2k0t. The
ratio c1:(c1 1 c2) was used to calculate dissociation constants.
Donor–acceptor spectral overlap gives a Fo¨rster distance (Ru-Fe
distance at which half the emission is quenched by energy
transfer; ref. 22) of R0 5 26.2 Å for the ferriheme enzyme and
R0 5 27.6 Å for the carbonmonoxy species. Ru-Fe distances, r,
were calculated by using the equation, ken 5 k0(R0yr)6.
Results and Discussion
Ru-substrates (Scheme 1) were modeled into the substrate-free
P450 crystal structure (23) to position ethylbenzene (EB) and Ad
at the active site and [Ru(bpy)3]21 at the protein surface.
Ru-Cn-EB and Ru-Cn-Ad were constructed by the covalent
attachment of EB and Ad to variable length methylene chains
[(CH2)7–13] terminating in the photosensitizer (6). An amide
functionality was incorporated into the Ru substrates to permit
hydrogen bonding, as occurs between Tyr-96 and camphor (15).
To generate Ru-ligands that could bind the heme iron (24),
imidazole was linked to alkyl-tethered [Ru(bpy)3]21 (Ru-Cn-Im).
Ru-EByAd compounds, as well as Ru-Im, have been shown to
bind P450 with high affinity (6). We have crystallized one of
these complexes, P450:Ru-C9-Ad, and structurally characterized
it to 1.55 Å (Fig. 1). The Ru-substrate binds as predicted, with
the Ad moiety mimicking substrate (25), a hydrogen bond
between Tyr-96 and the amide functionality, and [Ru(bpy)3]21 at
the mouth of a large channel that has opened to accommodate
the sensitizer.
Binding of the Ru-Cn-EByAdyIm compounds to the P450
target was detected by decreases in Ru21 excited-state (Ru21*)
lifetimes (6). [Ru-substrate]21* emission decay is normally
monophasic (k0 5 2.1 3 106 s21) but becomes biphasic with a
dominant fast component (ken 5 0.5 3 107 to 1.4 3 107 s21; k0
5 2.1 3 106 s21) in the presence of P450 (Fig. 2). Thus, on
addition of enzyme, the Ru-substrate or Ru-ligand partitions
between a ‘‘bound’’ state, in which Ru21* is quenched, and a
‘‘free’’ state, in which it is not. Photoexcitation of a P450:Ru-
Fig. 1. Crystal structure of the P450cam:Ru-C9-Ad complex. The Ru substrate is shown in yellow to highlight docking of [Ru(bpy)3]21 at the surface of the protein
as predicted by computer modeling and energy-transfer experiments. The methylene linker occupies a large channel from the enzyme surface to the heme. A
hydrogen bond connects the Ru-substrate amide carbonyl (red atom) to Tyr-96 (orange). The adamantyl moiety (center) resides at the P450 active site above the
heme (orange) in the same position as the natural Ad substrate (magenta), shown in superposition from the 4cpp crystal structure (25). Although both D and
L [Ru(bpy)3]21 enantiomers are present in the complex, only L is shown.
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C9-Ad single crystal yields a predominantly monophasic lumi-
nescence decay (Fig. 2) that is strongly quenched by the protein
(ken 5 1.1 3 107 s21), thereby confirming that the fast decay
component, ken, is attributable to P450:Ru-substrate complex
formation.
Competitive binding between Ru-substrates and camphor at
the active site is indicated by the ability of the natural substrate
(KD ’ 1 mM) to diminish the fraction of bound [Ru substrate]21*
decaying at the faster rate, ken. At the titration end point,
camphor completely displaces the Ru-substrate from P450, as
shown by monophasic Ru21* emission decay kinetics (k0 5 2.1 3
106 s21). Analysis of Ru-C11-Ad emission quenching by P450
yields a dissociation constant (KD 5 0.8 mM) in excellent
agreement with Ru-C11-Adycamphor competitive binding assays
monitored by UV-visible spectroscopy (KD 5 0.7 mM). Associ-
ation of Ru-substrates and Ru-ligands with P450 is sufficiently
strong to allow detection of the enzyme at submicromolar
concentrations (Table 1). The emission decay profile of Ru-
C9-Ad (2.5 mM) in 50 mM sodium phosphate buffer (pH 7) is
monophasic (k0 5 2.1 3 106 s21) in the presence of six heme
proteins (yeast cytochrome c, horse skeletal muscle myoglobin,
bovine lipase cytochrome b5, bovine liver catalase, recombinant
yeast cytochrome c peroxidase, and horseradish peroxidase),
each at 5 mM. Our finding that the addition of 500 nM P450cam
to this mixture yields biphasic Ru21* kinetics (’10% ken; ’90%
k0) indicates the feasibility of detecting specific biomolecules in
complex media.
Specificity of Ru substrates for P450 is controlled largely by
interactions of the substrate moiety with the active site. Partic-
ularly noteworthy is the fact that [Ru(bpy)3]21 is a sensitive
reporter of binding even for substrates that do not shift the heme
absorption spectrum by displacing ligated water (6). Dissociation
constants for Ru-Cn-EB compounds are the first presented for
derivatives of EB. The chain-length dependence of binding in the
Ru-Cn-EB series (KD 5 0.7–6.5 mM for n 5 7–13) shows that
detection of P450 by Ru-substrates may be fine tuned by
modification of the linker component. In the case of Im-
terminated tethers, however, Ru-C11-Im has no affinity for P450,
whereas Ru-C13-Im binds the enzyme tightly (Table 1). Appar-
ently, the shorter linker does not allow the Im to extend far
enough into the protein to ligate the heme iron.
Fo¨rster (dipole–dipole) energy transfer dominates the
quenching in P450:Ru-substrate complexes. Evidence that elec-
tron transfer does not contribute significantly to this quenching
is provided by the finding that ferriheme reduction by
[Ru(bpy)3]1 is ’103 times slower than ken (6). Spectral overlap
of [Ru(bpy)3]21* emission with the absorption of Fe(CO)21
P450 is greater than with the ferriheme enzyme, suggesting that
Fo¨rster energy transfer should be more efficient in the carbonyl
complex (where both oxidation and reduction of the heme–CO
complex are energetically disfavored). Not only is the decay of
Ru21* in P450 Fe(CO)21:Ru-C11-EB 1.5 times faster (ken 5
1.6 3 107 s21), the calculated Ru-Fe distances differ by only 0.4
Å for the two heme oxidation states (26, 27).
The Ru-Fe distance found in the P450:Ru-C9-Ad crystal (21
Å) is in excellent agreement with the Fo¨rster analysis of energy-
transfer kinetics for this complex in solution. Similar Ru-Fe
distances were calculated for the various Ru-substrates, suggest-
ing a common mode of Ru-substrate binding at the P450 active
site. The shallow Ru-Fe distance dependence on chain length in
the Ru-Cn-EB series confirms that [Ru(bpy)3]21 always binds
near the protein surface. The shortest EB derivatives, Ru-C7-EB
and Ru-C9-EB, report the minimum length of the substrate
access channel (19.5 Å). These data also indicate that the region
occupied by the methylene linker represents the most likely path
followed by natural substrates to access the P450 active center.
The swath cut by Ru-substrates in P450 is a channel of consid-
erable breadth (3–8 Å) and depth (’20 Å).
We have developed a method of sensing specific biomolecules
that involves tethering a photosensitizer to a molecule with high
affinity for an active site. Analysis of Ruyheme Fo¨rster energy-
transfer kinetics has revealed the dimensions and conforma-
tional f lexibility of the access channel and probed the mecha-
nism of substrate binding. This approach can be broadly ex-
panded through a combinatorial approach to designing substrate
moieties that target P450s as well as other enzymes, modifying
sensitizers to produce desired signals, and optimizing linkages to
enhance specificity or probe target conformations. Replacement
of [Ru(bpy)3]21 with osmium polypyridyl complexes (28) would
tune the emission further toward the near infrared, thereby
improving tissue penetration and optical detection over the
background of scattered light from cellular components. The
ability of sensitizer-linked substrates to detect proteins and
perform photochemical oxidation and reduction reactions at
specific enzyme active sites (6) opens avenues for intervention in
metabolic processes.
Fig. 2. Kinetics traces of [Ru-C9-Ad]21* emission decay at room temperature
in solution and in a single crystal of P450cam:Ru-C9-Ad. [Ru-C9-Ad]21* (10 mM)
shows monophasic decay (black). Emission decay of [Ru-C9-Ad]21* equimolar
with P450 (10 mM) is biphasic (red). In a P450:Ru-C9-Ad crystal, [Ru(bpy)3]21*
quenching is predominantly monophasic (blue). A secondary (,10%) slower
phase (k0 5 4.8 3 106 s21) also was observed, suggesting that a small percent-
age of the Ru substrate may remain unbound in the crystal. Faster
[Ru(bpy)3]21* emission decay, ken, in the crystal relative to solution most likely
reflects small conformational differences in P450 between the two phases.
Faster decay of the intrinsic [Ru(bpy)3]21* emission, k0, in the crystal is attrib-
utable to quenching by oxygen.
Table 1. Dissociation constants, Ru21* excited-state lifetimes,
and Ru-Fe distances
Compound KD, mM ken21, ns Ru-Fe, Å
[Ru-C13-EB]21* 1.7 6 0.4 107 6 8 20.6 6 0.2
[Ru-C12-EB]21* 1.5 6 0.3 103 6 7 20.5 6 0.2
[Ru-C11-EB]21* 0.9 6 0.4 94 6 7 20.1 6 0.3
[Ru-C10-EB]21* 0.9 6 0.4 88 6 2 19.9 6 0.1
[Ru-C9-EB]21* 0.7 6 0.1 75 6 2 19.4 6 0.1
[Ru-C7-EB]21* 6.5 6 1.3 77 6 2 19.5 6 0.1
[Ru-C11-Ad]21* 0.8 6 0.3 203 6 16 21.0 6 0.3
[Ru-C9-Ad]21* 0.7 6 0.2 231 6 11 21.4 6 0.2
[Ru-C13-Im]21* 4.1 6 1.1 190 6 8 21.2 6 0.1
[Ru-C11-Im]21* — 488 6 35 NA
Uncertainties represent one standard deviation of the data averaged from
three to six experiments.
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